SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
FDA Calendar Updates: BVX, HEB, HGSI, ONXX, SGP
ONXX
|
|
|
-23.47%
in
109 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 273 entries as of 7/22/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin...
|
Who's Next in the Biotech Buyout Frenzy?
ONXX
|
|
|
+20.30%
in
281 days
(closed on 07/22/09)
<> The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster their range of marketed products, late stage pipeline candidates, and drug discovery technology platforms.
Genentech (DNA) has rejected Roche's (RHHBY) $89 bid to acquire the remaining 44% of DNA it does not already own as insufficient. I think DNA could easily get $100 per share based on Eli Lilly's (LLY) $70 buyout of ImClo...
|
ONXX is a HOLD
ONXX
Not selling yet...
ONXX
|
|
|
+122.34%
in
1060 days
I played my cards right and bought as the stock dropped after Nexavar failed to be approved for the treatment of melanoma. I was already looking toward the possible approval of uses for other cancers such as liver.
ONYX may pull back into the low 20's over the next few months, but with the buyout possibilities and more firms watching this company (and buying) I am going to ride out those small bumps. If it drops below 22 I'll be buying more.
|
From the Blogosphere
Zacks #5 Rank Additions for Wednesday – Zacks Tale of the Tape
|
|
|
Here are the stocks added to the Zacks #5 Rank ("strong sell") List today: <> Administaff Inc (ASF) Allete Inc (ALE) American Equity Investment Life Holding Co (AEL) Applied Signal Technology Inc (APSG) Asset Acceptance Capital Corp (AACC) Build-A-Bear Workshop Inc (BBW) Capstone Turbine Corp (CPST) Cascade Corp (CASC) Cbeyond Inc (CBEY) Cheniere Energy Inc (LNG) Chesapeake Utilities Corp (CPK) China Telecom Corp Ltd (CHA) Commercial Metals Co (CMC) Empresa Brasileira de Aeronautica SA (ERJ) First Community Bancshares Inc (FCBC) <><>First Mariner Ban...
|
Onyx Beats Estimates – Analyst Blog
|
|
|
Onyx Pharmaceuticals (ONXX) reported third quarter earnings of 28 cents per share, well above the Zacks Consensus Estimate of 22 cents as well as 21 cents reported in the year-ago period. The company, along with Bayer AG (BAYRY.PK), developed Nexavar (sorafenib) tablets, an anticancer therapy currently approved and marketed for the treatment of liver cancer and advanced kidney cancer in the US, European Union, Japan and some other countries. Onyx’s earnings come in the form of royalty and collaboration income on Nexavar sales.
For the quarter, Onyx reported revenues of $69.1 million comp...
|
Zacks #5 Rank Additions for Friday – Zacks Tale of the Tape
|
|
|
Here are the stocks added to the Zacks #5 Rank ("strong sell") List today: <> Alliance HealthCare Services Inc (AIQ) American Equity Investment Life Holding Co (AEL) Amerigas Partners LP (APU) Michael Baker Corp (BKR) Cadence Financial Corp (CADE) Celadon Group Inc (CLDN) CRM Holdings Ltd (CRMH) DemandTec Inc (DMAN) Dixie Group Inc (DXYN) Encore Bancshares Inc (EBTX) Fair Isaac Corp (FICO) FelCor Lodging Trust Inc (FCH) First Marblehead Corp (FMD) First Place Financial Corp (FPFC) Hawk Corp (HWK) ICO Inc (ICOC) Independent Bank Corp (IBCP) ...
|
Onyx Pharmaceuticals: Could Acquiring Proteolix Be the Deal of the Year?
<>Onyx’s (ONXX) stock decline in the past few months puzzled its shareholders. Nothing that has come in the news in the past year has been bad. On the contrary, a string of promising results was incessantly coming from the clinical trials of the firm’s cancer drug Nexavar on a variety of cancers.  Now there are sufficient data to get an approval for other malignancies, including breast cancers. The drug was first approved for kidney cancer and then for liver cancer and, for a long while, there was no evidence that it would be approved for other cancers. Shareholders, though, did not lose ...
|
Onyx Pharmaceuticals: Is Nexavar the Next Avastin?
Nexavar, approved for kidney and lung cancer, is already a success by most measures. It should reach blockbuster status, surpassing $1 billion in worldwide annual sales by 2010. Most companies would be quite pleased to have a drug deliver such results, and Nexavar’s owners, Onyx Pharmaceuticals (ONXX) and Bayer AG (BYERF.PK), probably feel the same. However, at this stage in the drug’s life the important question for Onyx and Bayer is, “is Nexavar’s current progress is just the tip of the iceberg?” <>One needs only to look at the success of fellow anti-angiogenesis drug, Avastin,...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ONXX |
Visit streetinsider.com
More Resources
|
About ONYX Pharmaceuticals Inc.
- Answers.com
